A Novel Anti-HIV Activity of CCR6 via APOBEC3G: Relevance to CNS Infection
A Novel Anti-HIV Activity of CCR6 via APOBEC3G: Relevance to CNS Infection
批准号:
8128430
负责人:
Alfredo Garzino-Demo
金额:
$37.85万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-29 至 2014-08-31
关键词:
AIDS Dementia ComplexAnti-HIV AgentsAntiviral AgentsAntiviral TherapyAstrocytesBindingCCL20 geneCCL23 geneCCR6 geneCD4 Positive T LymphocytesCellsChemicalsClinicalCritical PathwaysDataDefensinsDendritic CellsDominant-Negative MutationEnzyme-Linked Immunosorbent AssayEpithelial CellsFlow CytometryHIVHIV InfectionsHIV SeropositivityInfectionKnowledgeLife Cycle StagesLigandsLymphaticMEKsMeasuresMediatingMicroarray AnalysisMicrogliaNeuraxisOrganPathway interactionsPatientsPeripheral Blood Mononuclear CellPertussis ToxinPhosphotransferasesPlayPreventionProgressive DiseaseProteinsReverse TranscriptionRoleSignal TransductionSmall Interfering RNASpecimenSymptomsT memory cellTestingTherapeuticViralVirusabstractingcell typechemokineinhibitor/antagonistinsightmacrophagemolecular massmutantnovelperipheral bloodpublic health relevancereceptorvirus host interaction
中文摘要
描述(由申请人提供):CCR 6通过APOBEC 3G的新的抗HIV活性:与CNS感染的相关性摘要我们已经表明,当防御素hBD 2和趋化因子MIP-31(CCL 20)与它们的细胞受体CCR 6结合时,它们诱导针对HIV的细胞内抗病毒活性,这在不表达CCR 6的细胞中是不存在的。虽然直接灭活包膜病毒,包括HIV已被牵连作为防御素的一种机制,据我们所知,通过CCR 6介导的HIV抑制是新的。该机制发生在进入后但在逆转录时或之前,并且似乎是由于细胞内抗病毒蛋白APOBEC 3G的表达增加。抑制被废除百日咳毒素,表明参与G1 i依赖的信号转导。CCR 6在与HIV感染高度相关的细胞上表达;它们包括记忆T细胞、树突状细胞、活化的巨噬细胞、小胶质细胞和Th 17细胞。与CCR 6结合的防御素主要由上皮细胞和星形胶质细胞表达,而MIP-31由粘膜上皮细胞、活化的外周血单核细胞和星形胶质细胞产生。由于CCR 6及其配体在中枢神经系统中与HIV感染高度相关的细胞中表达,因此靶向CCR 6的HIV抑制机制可能在控制HIV感染和CNS症状中起关键作用。此外,阐明受CCR 6激活限制的HIV生命周期中的细胞内途径和步骤可以提供感染早期病毒-宿主相互作用的见解,并确定抗病毒治疗的新靶点。我们提出鉴定APOBEC 3G作为原代细胞中CCR 6介导的抗病毒活性的效应分子;证明CCR 6诱导的信号转导增加APOBEC 3G表达并鉴定关键的特异性途径;证明CCR 6介导的HIV抑制对广谱的原代和非B病毒分离株的功效;并测定临床标本中CCR 6、CCR 6配体和APOBEC 3G的表达。
公共卫生相关性:这里提出的研究将调查一种称为CCR 6的细胞受体抑制HIV的机制。这些研究与HIV感染的预防和治疗高度相关,因为它们将为开发针对CCR 6的新型抗HIV药物提供知识。
英文摘要
DESCRIPTION (provided by applicant): A novel anti-HIV activity of CCR6 via APOBEC3G: relevance to CNS infection Abstract We have shown that when defensin hBD2 and chemokine MIP-31 (CCL20) bind to their cellular receptor, CCR6, they induce an intracellular antiviral activity against HIV that is absent in cells that do not express CCR6. While direct inactivation of enveloped viruses including HIV has been implicated as one mechanism of defensins, to our knowledge, HIV inhibition mediated through CCR6 is novel. The mechanism occurs post entry but at or before reverse transcription, and appears to be due to increased expression of the intracellular antiviral protein APOBEC3G. Inhibition is abrogated by pertussis toxin, suggesting the involvement of G1i-dependent signal transduction. CCR6 is expressed on cells that are highly relevant to HIV infection; they include memory T cells, dendritic cells, activated macrophages, microglia and Th17 cells. Defensins that bind to CCR6 are primarily expressed by epithelial cells and astrocytes, while MIP-31 is produced by mucosal epithelial cells, activated peripheral blood mononuclear cells and astrocytes. Since both CCR6 and its ligands are expressed in the central nervous system in cells highly relevant to HIV infection, an HIV suppressive mechanism that targets CCR6 may play a critical role in controlling HIV infection and CNS symptoms. Further, elucidation of the intracellular pathways and the step(s) in the HIV life-cycle limited by CCR6 activation could provide insights into virus-host interactions early in infection and identify new targets for antiviral therapy. We propose to identify APOBEC3G as the effector molecule of the antiviral activity mediated by CCR6 in primary cells; to demonstrate that CCR6- induced signal transduction increases APOBEC3G expression and identify what is the critical specific pathway; to demonstrate the efficacy of CCR6-mediated HIV inhibition on a broad spectrum of primary and non-B viral isolates; and to measure the expression of CCR6, CCR6 ligands, and APOBEC3G in clinical specimens.
PUBLIC HEALTH RELEVANCE: The studies proposed here will investigate the mechanism of inhibition of HIV by a cellular receptor called CCR6. These studies are highly relevant to prevention and treatment of HIV infection because they will contribute knowledge that can be used to develop novel anti-HIV drugs that will target CCR6.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Anti-HIV Activity of CCR6 via APOBEC3G: Relevance to CNS Infection
-
批准号:8293500
-
项目类别:
-
资助金额:$0.97万
-
财政年份:2009
-
负责人:Alfredo Garzino-Demo
-
依托单位:
A Novel Anti-HIV Activity of CCR6 via APOBEC3G: Relevance to CNS Infection
-
批准号:7840803
-
项目类别:
-
资助金额:$33.75万
-
财政年份:2009
-
负责人:Alfredo Garzino-Demo
-
依托单位:
A Novel Anti-HIV Activity of CCR6 via APOBEC3G: Relevance to CNS Infection
-
批准号:8319412
-
项目类别:
-
资助金额:$33.08万
-
财政年份:2009
-
负责人:Alfredo Garzino-Demo
-
依托单位:
A Novel Anti-HIV Activity of CCR6 via APOBEC3G: Relevance to CNS Infection
-
批准号:8529631
-
项目类别:
-
资助金额:$31.92万
-
财政年份:2009
-
负责人:Alfredo Garzino-Demo
-
依托单位:
HIV suppression by Beta-defensins
-
批准号:6773967
-
项目类别:
-
资助金额:$22.28万
-
财政年份:2003
-
负责人:Alfredo Garzino-Demo
-
依托单位:
HIV suppression by Beta-defensins
-
批准号:6695377
-
项目类别:
-
资助金额:$22.28万
-
财政年份:2003
-
负责人:Alfredo Garzino-Demo
-
依托单位:
海外基金